ArticleNature medicine2020
Resistance looms for KRAS
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research trends in immunotherapy for non-small cell lung cancer patients with KRAS mutations: a bibliometric analysis.Frontiers in oncology · 2024Pooled it
- What Are the Practical Applications of Single-Cell Proteomics?Proteomes · 2026Article
- Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development.Nature communications · 2025Article
- Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond.Frontiers in pharmacology · 2025Review
- Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.Journal of the National Cancer Institute · 2024Article
- Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRASJournal of proteome research · 2023Article
- Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRASbioRxiv : the preprint server for biology · 2023Article
- RAS nanoclusters are cell surface transducers that convert extracellular stimuli to intracellular signalling.FEBS letters · 2023Review
- Covalent inhibitor targets KRasGenes & diseases · 2023Review
- TargetingGastroenterology report · 2023Review
- Insights into protein post-translational modification landscapes of individual human cells by trapped ion mobility time-of-flight mass spectrometry.Nature communications · 2022Article
- Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers.Cancer research · 2022Article
- Drugging KRAS: current perspectives and state-of-art review.Journal of hematology & oncology · 2022Review
- Targeting KRAS in PDAC: A New Way to Cure It?Cancers · 2022Review
- AZD4625 is a Potent and Selective Inhibitor of KRASG12C.Molecular cancer therapeutics · 2022Article
- Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells.Cancer communications (London, England) · 2022Article
- Daily Practice Assessment ofCancers · 2022Review
- Direct TargetingCancers · 2022Review
- Biochemical characterization of the interaction between KRAS and Argonaute 2.Biochemistry and biophysics reports · 2022Article
- The path to the clinic: a comprehensive review on direct KRASJournal of experimental & clinical cancer research : CR · 2022Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32020086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.